Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-5500 + Nubeqa
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
VIR-5500 + Nubeqa is an investigational combination regimen consisting of VIR-5500 (also known as AMX-500 or SAR-446329) and Nubeqa (darolutamide). VIR-5500 is a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN dual-masked T-cell engager (TCE) designed to bind PSMA on prostate cancer cells and CD3 on T cells. The PRO-XTEN masking technology keeps the TCE inactive in systemic circulation, with activation occurring selectively in the tumor microenvironment via cleavage by tumor-associated proteases, thereby minimizing systemic toxicities such as cytokine release syndrome (CRS). Nubeqa (darolutamide) is an oral, non-steroidal androgen receptor inhibitor that competitively inhibits androgen binding, receptor nuclear translocation, and receptor-mediated transcription. The combination is being evaluated in a Phase 1 clinical trial for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- Other names
- AMX-500 + darolutamideAMX-500 + Nubeqadarolutamide + AMX-500darolutamide + SAR-446329darolutamide + SAR446329darolutamide + VIR-5500Nubeqa + AMX-500Nubeqa + SAR-446329Nubeqa + SAR446329Nubeqa + VIR-5500SAR-446329 + darolutamideSAR-446329 + NubeqaSAR446329 + darolutamideSAR446329 + NubeqaVIR-5500 + darolutamideVIR-5500 + Nubeqa
02
Targets
AR (Adrenergic receptors)PSMA (Prostate-specific membrane antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on VIR-5500 + Nubeqa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-5500 + Nubeqa.